Alnylam Pharmaceuticals Inc logo

Alnylam Pharmaceuticals Inc

ALNY
Healthcare|Biotechnology|USA
$298.76
-14.03 (-4.49%)
Tangible Book
$8.06
Graham Number
$32.23

About

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Stock Price

-7.4%(1Y)

Pipeline Summary

95 total trials
36
Phase 1
35
Phase 2
15
Phase 3
0
Phase 4
Completed: 49Terminated: 10Active: 3NO_LONGER_AVAILABLE: 1Recruiting: 22Withdrawn: 3NOT_YET_RECRUITING: 2APPROVED_FOR_MARKETING: 3ENROLLING_BY_INVITATION: 1Unknown: 1

Active Trials (25)

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
NCT06360289Hereditary Amyloidosis, Transthyretin-Related
Active
Enrollment: 346 participants
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
NCT07465224Type 2 Diabetes Mellitus (T2DM)
Phase 2Recruiting
Enrollment: 40 participants
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
NCT05040373Hereditary Transthyretin-mediated (hATTR) Amyloidosis
Recruiting
Enrollment: 10 participants
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
NCT07295717Healthy Volunteers
Phase 1Recruiting
Enrollment: 76 participants
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727Alzheimer's Disease
Phase 1Recruiting
Enrollment: 50 participants
View all 25 active trials →

BioScore

7.2/10
Buy

Ownership

Recent Insider Trades

PYOTT DAVID E ISELL
2026-06-013,830 shares @ $299.18
McLaughlin MelissaSELL
2026-04-063,910 shares @ $325.92
Garg PushkalSELL
2026-03-054,713 shares @ $323.53
Fitzgerald Kevin JosephSELL
2026-03-051,291 shares @ $323.54
Greenstreet YvonneSELL
2026-03-042,933 shares @ $323.08

Recent News

2026-07-10 14:32:25
2026-06-29 10:31:12
2026-06-25 20:00:14
Data last updated: Jul 12, 2026, 07:25 PM